Incyte Corp (INCY)

Add to Watchlists
Create an Alert
Quickflows
85.97 -0.96  -1.10% NASDAQ Sep 23, 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All INCY News

News

View All Events

Events

Date Type Description
10/29/2020 08:00 EDT Misc Incyte Corp Third Quarter Earnings Conference Call for 2020
10/29/2020 Earnings Incyte Corp Third Quarter Earnings for 2020 Release
08/04/2020 08:00 EDT Misc Incyte Corp Second Quarter Earnings Conference Call for 2020
08/04/2020 07:00 EDT Earnings Incyte Corp Second Quarter Earnings Results for 2020
05/26/2020 13:00 EDT Misc Incyte Corp Annual General Meeting for 2019
05/05/2020 08:00 EDT Misc Incyte Corp First Quarter Earnings Conference Call for 2020
05/05/2020 Earnings Incyte Corp First Quarter Earnings Result for 2020
02/13/2020 08:00 EST Misc Incyte Corp Fourth Quarter Earnings Conference Call for 2019
02/13/2020 07:00 EST Earnings Incyte Corp Fourth Quarter Earnings Results for 2019
02/13/2020 Misc Incyte Corp Annual Report for 2019
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 2.388B
Total Expenses (TTM) 2.572B
Net Income (TTM) -191.07M

Balance Sheet View Statement

Total Assets (Quarterly) 3.212B
Total Liabilities (Quarterly) 867.72M
Shareholders Equity (Quarterly) 2.345B

Cash Flow Statement View Statement

Cash from Operations (TTM) -12.00M
Cash from Investing (TTM) -169.56M
Cash from Financing (TTM) 91.12M

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.incyte.com
  • Investor Relations URL: http://www.incyte.com/ir/investor-overview.aspx
  • HQ State/Province: Delaware
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Oct. 29, 2020
  • Last Earnings Release: Aug. 04, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 85.97
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
BBH VanEck Vectors Biotech ETF 3.65%
FBT First Trust NYSE Arca Biotech ETF 3.19%
VGHCX Vanguard Health Care Inv 2.30%
ARKG ARK Genomic Revolution ETF 2.25%
IBB iShares Nasdaq Biotechnology ETF 2.01%
THISX T. Rowe Price Health Sciences I 1.80%
HQH Tekla Healthcare Investors 1.77%
VCHSX VALIC Company I Health Sciences 1.57%
RPG Invesco S&P 500® Pure Growth ETF 1.29%
MEFNX MassMutual Select Mid Cap Growth R3 1.03%
RPTTX T. Rowe Price Diversified Mid Cap Gr I 0.80%
VADRX Invesco Equally-Wtd S&P 500 R 0.22%

Comparables

Edit
GILD Gilead Sciences Inc
LLY Eli Lilly and Co
ALXN Alexion Pharmaceuticals Inc
REGN Regeneron Pharmaceuticals Inc
MOR MorphoSys AG

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.